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Processes inside the human body are driven by cellular machines called enzymes. 
Sometimes, these enzymes are involved in changing genetic material to fulfill a purpose. 
This paper discusses enzymes involved in changing the genetic material of humans and 
viruses. These enzymes have recently been found to target genetic material in cancerous 
tissue. The genetic material of cancerous tissue has unique differences when compared to 
healthy genetic material. Specifically, cancerous tissue tends to create its own 
environment in the body that promotes change in the genetic material. In some cases, this 
can mean the genetic material is more likely to be damaged. Given this fact, the authors 
of this thesis wanted to know if, the enzymes discussed within, acted differently on 
damaged genetic material when compared to how they act on healthy genetic material. 
We found that the enzymes were just as affective at acting on the damaged genetic 












AID/APOBEC3s are endogenous enzymes that deaminate deoxycytidine (dC) to 
deoxyuridine (dU). Although they can mutate any dC, each family member has a unique 
sequence preference determined by nucleotides immediately surrounding the target dC. 
This WRC (W=A/T, R=A/G) and YC (Y=T/C) preference is well established for AID 
and APOBEC3A/B respectively. Common sources of DNA damage such as alkylation 
and oxidation alter the chemistry of normal base side chains prompting us to examine the 
activity of AID, APOBEC3A, and APOBEC3B on dCs whose neighboring -2 or -1 
position bases are damaged through oxidation or alkylation. We found that all three 
enzymes efficiently deaminate dC when common damaged bases are present in the -2 and 
-1 positions. Strikingly, some of these motifs supported even higher catalytic efficiencies 
by AID, APOBEC3A and APOBEC3B compared to WRC/YC motifs which are their 
most favored normal DNA sequences. Based on interactions of the surfaces of AID, 
APOBEC3A and APOBEC3B with DNA as resolved by structural studies, we then 
modeled interactions with alkylated or oxidized bases. Corroborating the enzyme kinetics 
experiments, these analyses suggest that the surface regions responsible for recognition of 
normal bases can also interact with oxidized and alkylated bases. Thus, our data extend 
the current knowledge of the -2 and -1 position substrate sequence specificity of AID/A3s 
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1.1 AID and the APOBEC family of cytidine deaminases: DNA-editing enzymes mediating 
diverse biological functions 
AID/APOBECs are cytidine deaminases that convert deoxycytidine (dC) to deoxyuridine 
(dU) [1, 2]. The AID/APOBEC family of proteins represents a group that fulfills diverse 
physiological functions. The protein family comprises eleven members in humans: AID and 
APOBEC1 (genes located on chromosome 12), APOBEC2 (gene located on chromosome 6), 
seven APOBEC3 proteins (APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, 
APOBEC3F, APOBEC3G, APOBEC3H; genes located on chromosome 22) and APOBEC4 
(gene located on chromosome 1) . AID and APOBEC2 are considered the ancestral members 
of the AID/APOBEC family, whereas APOBEC1 and APOBEC3 evolved later and are similar 
to AID [1-20]. APOBEC3 proteins are detectable exclusively in mammals [3]. All members of 
the AID/APOBEC family share at least one zinc-binding catalytic domain with the consensus 
amino acid sequence H-X-E-X23–28-P-C-X2–4-C (X stands for any amino acid) [3]. APOBEC1 
was the first to be isolated and is active in mutating C’s to U’s in mRNA for apolipoprotein B. 
This results in Apolipoprotein 48 which is involved in lipid uptake from the intestine [3]. 
APOBEC2 was the next to be discovered. APOBEC2 is expressed in skeletal muscle and the 
heart but currently has never been shown to be mutagenic in yeast or bacterial assays. Its exact 
physiological role has yet to be identified, however its expression is crucial for muscle 
development [1-4]. APOBEC4 is expressed in the testicles. It is thus far inactive in yeast and 




Figure 1.1. The AID/APOBEC family of enzymes. Enzymatic family tree is derived based 
on comparison and similarities between protein structure of the main catalytic subunit between 
each enzyme in the family. In the case of double-domain enzymes, comparison is made between 
the N-terminal domain and single catalytic subunits of each other double-domain enzyme or 
single-domain enzyme in the family respectively. Structural similarity garnered from 
information found in Conticello et al. 2005 [11]. 
 
The APOBEC3 sub-branch members, including APOBEC3A (A3A), APOBEC3B (A3B),  
APOBEC3C (A3C), APOBEC3F (A3F), APOBEC3G (A3G) and APOBEC3H (A3H) function 
as cellular anti-viral machinery by acting on retroviral genomes and mobile endogenous 
retroelements [5-12]. The APOBEC3 family members can be further classified based on 
number of zinc-binding domains. A3A, A3C and A3H have single zinc-binding domains. In 
contrast, A3B, A3D, A3G and A3F have two zinc-binding domains [5-12]. Their specific 
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physiological functions differ between each sub-branch member. Indeed, as this group of 
enzymes has only been discovered in the last 18 years, there are still those whose functions are 
unknown. However, they are all functional deaminases, are widely expressed in multiple tissue 
types and are associated with antiviral activity [7,8,13].  
APOBEC3A acts mostly on ssDNA and seems to be involved in cell-cycle arrest. Its exact 
cellular role is unknown, but in one experiment, caused clearing via deamination of dC’s in 
97% of foreign bacterial DNA [8]. Notably, A3A and A3B are extremely similar and share 
~95% amino acid sequence [1-3]. They have both been shown to deaminate the lagging-strand 
in DNA replication bubbles and thus may also be involved in signalling during replication [5]. 
Both, along with the other A3 family members are involved in cellular defense against many 
viruses such as Hepatitis B virus, Hepatitis C virus, human papillomavirus, human 
herpesviruses and T-Cell leukemia virus type-1 [9]. However, A3A/B are the members of the 
A3 family whose mutational signatures have been more prevalent in human cancer genomes 
than their A3 family members and thus are of particular interest which will be discussed in 
more detail later. A3D/F/G/H have been found to more specifically target retroviral genomes 
and endogenous transposons, specifically Human-Immunodeficiency Virus. APOBEC3G was 
found to be the most specific endogenous defense factor against Vif-deficient HIV virus. A3G 
is packaged into HIV virions and mutates the viral genome within, causing the genome to be 
mis-read and create ineffective translational products [7-9].  
AID is primarily expressed in activated B cells and mutates the immunoglobulin (Ig) loci, 
initiating somatic hypermutation and class switch recombination of antibodies [3, 4]. AID 
deaminates dC thereby generating dU within the immunoglobulin (Ig) locus [3-8]. Since uracil 
base pairs with adenine, unrepaired uracils lead to dC>dT transition mutations after DNA 
4 
 
replication, whereas error prone DNA repair of uracil lesions result in mutations at dC:dG as 
well as dA:dT base pairs. The repair of deaminated cytosines within switch regions, 5′ of the 
constant regions of antibody genes, leads to the generation of Double-Stranded Breaks (DSBs), 
which are a prerequisite for class switch recombination [3-8]. Hence, deficiency of functional 
AID in humans due to homozygous deletions or mutations causes the autosomal recessive form 
of an immunodeficiency syndrome, hyper-IgM syndrome. Disruption of AID in the chicken B 
cell lymphoma cell line DT40 abolishes antibody diversification by gene conversion. First 
studies suggested that the enzyme edits RNA intermediates, before it could be shown in vitro 
that AID deaminates ssDNA during transcription, preferentially the dC within WRC motifs [3-
8].  
It is well established that off-target AID-induced deamination events are involved in 
tumorigenesis and cancer genome mutagenesis [13-21]. More recently, it has come to light that 
expression and mutagenesis footprints of A3A and A3B are also prevalent in tumors arising 
from a wide range of tissues including bladder, breast, cervix and thyroid cancer, lung 
adenocarcinoma, B cell lymphomas, multiple myelomas, acute lymphoblastic leukemia and 
chronic lymphocytic leukemia [7,8,13-34]. 
Mutations are a basis for evolution and the development of genetic diseases [7,8]. Especially 
in cancer, somatic mutations in oncogenes and tumor suppressor genes alongside the occurrence 
of passenger mutations have been observed by recent deep-sequencing approaches. Mutations 
have long been considered random events induced by DNA-replication errors or by DNA 
damaging agents [1-5, 7-9]. However, the advent of genome sequencing led to the discovery of 
non-random mutation signatures in many human cancers. Common non-random mutations 
comprise DNA strand-biased mutations and mutations restricted to certain DNA motifs, which 
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recently have become attributed to the activity of the AID/APOBEC family of DNA 
deaminases. Hence, AID/APOBEC enzymes, which have evolved as key players in natural and 
adaptive immunity, have been proposed to contribute to cancer development and clonal 
evolution of cancer by inducing adjunct genomic damage due to their DNA deaminating 
activity [1-15]. 
     AID/A3s act on single-stranded DNA (ssDNA) substrates. They are loosely targeted 
throughout the genome and are understood to mutate readily accessible and unpaired ssDNA 
regions, such as those present during transcription and/or replication [35-47].  Once targeted 
to a stretch of the genome by these ssDNA-generating cellular mechanisms, AID/A3s can 
mutate any given dC; however, each enzyme exhibits a local target sequence preference based 
largely on the -2 and -1 nucleotides immediately upstream of the target dC. AID favors WRC 
(W=A/T, R=A/G) trinucleotides in in vitro enzyme assays, when exogenously expressed in 
bacteria or cell lines, as well as in vivo [42, 48-55]. In contrast, A3A/B/C/D/F favor dC in the 
YC dinucleotide context [46, 56-61]. A3G and A3H have a more specific preference for CCC 
trinucleotide sequences, mutating the third cytosine in the trinucleotide [3-8]. Since these 
signature “hotspots” are unique, they are relied upon to infer the mutational footprints of 
particular member(s) of the AID/A3 family in the context of sequenced viral genomes and 
tumor cell genomes.  Notably, these substrates have been studied on a variety of substrates in 
vivo such as small ssDNA fragments, “bubble” substrates whereby some of the DNA contains 
mismatched base pairs to create a bubble of ssDNA within an annealed dsDNA 
oligonucleotide, and complete sequences of DNA vectors within living prokaryotic and 
eukaryotic cultures [26,28-29,31,37,40,46]. However, the activity of these enzymes on each of 
these substrates have never been compared to one another in a formal holistic study to date.  
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Structurally, the core catalytic pocket is relatively conserved amongst AID/A3 enzymes 
[1, 56, 62-66]. Their differential sequence specificity is mediated by a substrate specificity 
loop (L7: the 4-4 connecting loop) that is highly divergent amongst AID/A3 members, and 
if swapped can transfer the sequence specificity of the donor [67]. In AID, a minor contribution 
has also been shown for L1 (the 1-1 connecting loop) [54, 67, 68]. Differences in the length 
and composition of this substrate specificity loop yield varying surface topologies proximal to 
the catalytic pocket, which underlies differing preferences for surface interactions with 
pyrimidine or purine bases at the -2 and -1 positions relative to the target dC [46, 55-57, 61, 
65]. 
   In contrast to the enzyme structural basis of sequence specificity in AID/A3s, this issue has 
also been investigated from the nucleic acid structure perspective. One approach has been 
probing AID/A3 activity on substrates containing various sequence arrangements including the 
four canonical DNA bases or naturally occurring analogues. In regards to the chemistry of the 
-2 and -1 bases, this approach has revealed that AID/A3s can recognize subtle differences in 
the pyrimidine or purine side chains of the -1 and -2 nucleotide positions relative to dC [42, 
56].  In contrast to limited information on the important chemical aspects of the -2 and -1 
position bases for AID/A3 recognition, chemical determinants of the target dC itself have been 
more rigorously investigated.  For instance, it has been suggested that some AID/A3 enzymes 
can function in genome demethylation through deamination of 5-methyl-cytidine(mC) [69-75]. 
We and others compared AID/A3 activities on substrates containing normal dC, mC, or 
deoxycytidines with other bulky adducts resulting from oxidation or methylation intermediates. 
It was found that AID has minimal activity on mC, roughly an order of magnitude weaker 
compared to dC. A3A and A3B also deaminate mC with less efficiency than dC. A3H 
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deaminates mC with equal efficiency to the native dC or rC. Overall, A3 activity on mC is 
significantly more robust compared to that of human AID [76-87]. Due to their function in 
deaminating methylated cytidines, it is postulated that AID/A3 enzymes are highly involved in 
gene expression. AID and several of the A3 enzymes such as A3B are localized to the nucleus 
of the cell, thus giving them greater potential access to methylated genes [76-78]. Further 
research is required to fully understand the epigenetic role of these enzymes. 
1.2 DNA damage and its role in the tumor micro-environment 
  In addition to off-target and deregulated deamination events, genomes of both somatic 
and cancer cells are also susceptible to environmental and chemical sources of DNA damage, 
such as reactive oxygen species (ROS), components of tobacco smoke, or chemotherapeutic 
drugs. Many of these agents instigate genome damage through alkylating or oxidizing normal 
DNA bases, thus altering their side chain chemistries [88-96]. Although repaired efficiently 
in healthy cells, oxidized and alkylated bases are often found in high abundance in cancer 
genomes due to deficiencies in their associated DNA repair pathways and being induced 
through chemotherapy treatment [93, 94, 97-115].  
As eluded to previously, DNA damage can take the form of oxidation, alkylation, radiation, 
or deamination. Each type of damage alters the structure of DNA which can cause read-through 
errors by DNA polymerases and RNA polymerases [90, 92-101]. Some structural changes that 
may occur are more harmful then others and can range from causing single-base mutations, 
such as in the case of an 8’-oxo-deoxygaunosine (8oxoG) //Adenosine Hoogsteen base-pair, to 
the complete stalling of genome replication such as in the case of 1-methyl-adenosine [103-
105]. Oxidation occurs when a cellular environment is saturated with ROS. The oxidative free 
radicals react with DNA nucleotides to create oxygenated derivatives such as the oxygenated 
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8’ carbon in 8oxoG [105-107, 112]. Alkylative damage occurs when an alkylating species 
containing a reactive methyl group encounters a DNA nucleotide, which causes the donation 
of the free methyl group to the base. Oxidative and alkylative damage are derived from 
different sources but cause similar results within the DNA chain. Specifically, the modified 
nucleotides become molecularly large adducts compared to the non-damaged native nucleotide 
counterparts. These bulky adducts can cause mispairing between nucleotides, such as an 
8oxoG // A mis-pair, or more commonly lead to DNA lesions [90-114]. These DNA lesions 
are points in the DNA tertiary structure which become ‘kinked’ due to the presence of a bulky 
DNA adduct.  One of the most impactful results of DNA lesions is known as a double-strand 
break (DSB). Double-strand breaks occur when the helical backbone of two DNA strands are 
“snapped” due to stress caused from structural change. Double-strand breaks occur naturally 
during meiosis in DNA replication, and during VDJ recombination in mature B cells [90-114]. 
However, they also occur at undesirable points in the cell cycle due to toxin exposure. DSBs 
can occur due to radiation, oxidation, or alkylation caused by a variety of sources. These 
sources include chemotherapeutics, radioactive tracing agents, and many common carcinogens 
such as Asbestos. [112-115]. DSBs are also often preceded by single-strand breaks and often 
occur at the ends of chromosomes due to defective metabolism of telomeres [90-114].  
In order to maintain a healthy genome, each cell must have an active response against DNA 
damage. An estimated 120,000 DNA lesions per cell occur every day [101]. Thus, each cell 
must maintain a constant balance between DNA damage and repair [90-114]. If DNA damage 
accumulates, there are several results that may follow [97, 100-105]:  
1. The DNA is repaired as normal and the cell continues normal function.  
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2. The cell may enter cell cycle arrest causing cellular senescence, eventual apoptosis may 
occur. 
3. The cell may enter a state of rapid mutation and cell cycle amplification, becoming 
cancerous. 
In order to prevent tumorigenesis, there are several mechanisms within a healthy cell that 
aid in DNA repair and maintenance. The conglomeration of these mechanisms is known as the 
DNA Damage Response (DDR). In order to respond to DNA damage, cellular machinery must 
play several key roles. The first of these roles are DNA damage sensors. The sensors perform 
the key role of detecting damage to the genome and providing initiation signals for the DDR. 
Once damage has been detected and the DDR has been initiated, signal transducers serve to 
transmit and amplify the signal. Finally, effectors receive the amplified signal and begin 
repairing DNA, activating cell cycle arrest, apoptosis, or cellular senescence [97, 100-105].   
DNA repair can be subcategorized into several components. For each type of damage, there 
must be an appropriate response. The first form of repair comes in the form of base excision 
repair (BER). The base excision repair pathway corrects most DNA adducts efficiently. The 
first step in this pathway is to hydrolyze the DNA adduct and create an abasic site. This 
function is performed by a variety of cellular DNA glycosylases such as the alkylpurine DNA 
glycosylases which are responsible for excising large methylated DNA adducts. An example 
of an alkylpurine glycosylase is N-methylpurine glycosylase (MPG) which is the enzyme 
responsible for excising 3-methyadenine [100-105]. Many DNA adducts have glycosylases 
which have evolved specifically to remove them, however there are also glycosylases which 
can remove a variety of adducts.  Once an abasic site has been created, it can be processed by 
one of two sub-pathways: single-nucleotide BER (SN-BER) and long-patch BER (LP-BER). 
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SN-BER is initiated by the cleavage of the DNA backbone by apurinic / apyrimidinic (AP) 
lyase at the 3’ end of the abasic site. AP lyase leaves a 3’ deoxyribose phosphate and a 5’ 
phosphate which temporarily block DNA polymerase activity. An AP endonuclease then 
cleaves the 3’deoxyribose phosphate and the 5’ phosphate is removed by a polynucleotide 
kinase/phosphatase. This leaves a single empty DNA slot which is quickly filled by a DNA 
polymerase. LP-BER is initiated via an AP endonuclease which cleaves the abasic site at the 
3’ end leaving only a 3’ hydroxyl site. The 3’ hydroxyl site can act as a direct substrate for 
DNA polymerases. Once filled, the nick in the DNA is closed by a DNA ligase leaving a fully 
repaired DNA site. The process that determines whether SN or LP BER is initiated remains a 
mystery, but it is suspected that the BER scaffold protein X-ray repair cross-compleneting 
protein 1 (XRCC1) plays a role [100-105, 112-115].  
Direct lesion reversal (DLR) is responsible for the repair of many large methylated DNA 
adducts such as O6-methylgaunine. DLR is a one step pathway that utilizes enzymes which 
directly catalyze the reverse reaction to that which formed the DNA adduct. For example, if a 
guanine is methylated to form an O6-methylgaunine by interaction with an alkylating species, 
the enzyme O6-methylgaunine methyltransferase directly removes the methyl group, restoring 
the guanine to its original form without a multi-step process [100-105, 112-115].  
The last form of single nucleotide repair is Nucleotide Excision Repair (NER). This 
pathway is responsible for repairing lesions formed from radioactive crosslinking such as 
cyclobutane pyrimidine dimerization (CPD) through photo-reversal. Briefly, a protein known 
as Phr1 contains two chromophores, Flavin-adenine Dinucleotide (FADH-) and 
Methylenetetrahydro folate (MTHF). Photoreversal occurs when Phr1 binds to a CPD 
containing DNA strand. MTHF absorbs a photon and transfers the excitation to FADH-. FADH 
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then transfers an electron to the CPD which causes unstable dimerization. The DNA reverts to 
its native duel monomer state and transfers an electron back to the enzyme so that it may be 
re-used for catalysis [109-115]. 
The previously described repair mechanisms are constantly active within cells during 
healthy cellular states. However, when DNA damage burden increases and causes genomic 
instability, SSBs and DSBs can wreak havoc on the cellular genome. When these breaks occur, 
several more complicated repair mechanisms are initiated. These repair mechanisms include 
SSB repair and DSB repair through Homologous Recombination and Non-Homologous End 
Joining. If these repair mechanisms are unsuccessful or the DNA damage is too severe, cell 
cycle arrest and apoptosis will be initiated [109-115].  
As mentioned previously, in order to initiate the DDR, sensor cellular machinery must be 
activated. These sensors are mainly the MRE11-RAD50-NSB1 (MRN) complex or Poly(ADP-
ribose) Polymerase 1 (PARP1). These sensors work by recruiting the apical kinases Ataxia 
telangiectasia mutated or Ataxia telangiectasia Rad3-related which are the signal transducers. 
These kinases begin the large phosphorylation cascade that will begin the signal amplification 
and determine which damage response pathway will be activated [97,100-105], they recruit 
the effectors. The first of these response pathways I will discuss is Single-Strand Break Repair 
(SSBR).  
First and foremost, SSBR requires that the SSB has ‘clean ends’. This means that at the 
break point there is a 3’ Hydroxyl deoxyribose nucleotide monophosphate (dNMP) and a 5’ 
Phosphate dNMP. However, this is often not the case and ‘dirty ends’, that will not allow repair 
machinery to act on them, exist instead. However, these ‘dirty ends’ can be processed through 
two pathways. 3’ ends can be processed by DNA glycosylases/ AP lyases, while 5’ ends can 
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be processed by DNA Polymerases and/ or 5’ flap endonuclease activity. Once the ends have 
been processed and are ‘clean’, repair can begin.  One of the main components of SSB repair 
is the protein XRCC1. While having no enzymatic activity of its own, XRCC1 is involved in 
scaffolding for SSB and BER. It has many interactions with enzymes such as OGG1, APE 1 
and MPG, glycosylases and endonucleases which were mentioned previously. However, its 
main function is in recruitment for SSB repair scaffolding. XRRC1 deficient cells show a 3-4 
fold reduced SSB rejoining and a 4-6 fold increase in chromosomal breakage [88-115].  After 
activation by PolyADP-ribose Polymerase 1, XRCC1 complexes with its partners LiG3α and 
RPA. It can then recognize the damaged DNA and forms scaffolding for DNA Polymerase δ 
and several DNA Ligases which insert new bases and rejoin the SSB [109-115].  
The final two main repair pathways in repairing chromosomal breakage are centred around 
DSBs. The first and preferred form of DSB repair is Homologous Recombination (HR). HR 
rejoins DSBs using a sister homolog as a template strand. As a result, this method of repair is 
very high fidelity. Initial steps in this pathway involve the generation of small single-strand 
regions at both ends of the break (similar to how one would begin to build a bridge). These are 
formed by DNA polymerases. Meanwhile the damage has been sensed by MRN which signals 
ATM or ATR (depending on the point of the cell cycle) to begin the phosphorylation cascade. 
Once these single-stranded regions have been formed, RAD51 recombinase is delivered to the 
site of the break via Breast Cancer Gene 2 (BRCA2) and Partner and localizer of BRCA 2  
(PALB2). Both BRCA2 and PALB2 are key tumor suppressor genes, which will be discussed 
later. Many members of the Rad protein family are actually ubiquitins, which has implicated 
ubiquitination in DSB repair [97, 100-105, 112-115]. RAD51 invades the gap in the DNA with 
the template strand creating what is known as a Holliday junction. XRCC2 and XRCC3 aid in 
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scaffolding during this process. Once this junction has been created, DNA synthesis occurs 
using the sister strand as a template. This is followed by branch migration and eventual 
resolution of the heteroduplex, forming a complete/repaired DNA helix.  It should be noted 
that HR mostly occurs at replication forks and thus most often occurs during S Phase and G2 
of the cell cycle in replicating DNA [97, 100-105, 112-115]. 
Non-Homologous End Joining (NHEJ) occurs at all other areas of DSBs where replication 
is not involved and is the predominant form of DSB repair in mammals. It is also the form of 
repair that occurs during VDJ recombination in B-cells. It most often occurs in G1 phase of 
the cell cycle. NHEJ has much lower fidelity then HR and is somewhat prone to error [111-
115]. Since it is often the primary way DSBs are repaired, its low fidelity and error prone state 
may mean NHEJ errors are often responsible for cell cycle arrest or tumorigenesis. NHEJ starts 
with signal initiation by MRN. ATM or ATR begin signal transduction much as in HR. The 
proteins Ku70 and Ku80 dimerize and bind to the end of DNA DSBs. This in turn recruits the 
DNA-dependant protein kinase to the site of damage. Activated DNA-PKcs complex recruits 
Artemis, XRCC4, DNA Ligase 4 (LIG4), and DNA Polymerase µ. Artemis has endonuclease 
activity necessary to provide the DNA ends for ligation and gap filling by LIG4 and DNA Pol 
µ. This results in a completed DSB repair without requiring a sister chromosome as a template 
strand [97, 100-105, 112-115].. 
Chemotherapeutics are anticancer drugs which can be used either singularly, or in a 
combination as a regimen. There are many types of chemotherapeutics. Alkylating species, 
such as cyclophosphamide and cisplatin, are so named because of their ability to alkylate many 
molecules. Alkylating species act on proteins, RNA and DNA [97-101]. This ability to 
bind covalently to DNA via their alkyl group is the primary cause for their anti-cancer 
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effects. DNA is made of two strands and the molecules may either bind twice to one strand of 
DNA (intra-strand crosslink) or may bind once to both strands (inter-strand crosslink) [98]. If 
the cell tries to replicate crosslinked DNA during cell division, or tries to repair it, the DNA 
strands can break. This leads to a form of programmed cell death called apoptosis. Alkylating 
agents will work at any point in the cell cycle and thus are known as cell cycle-independent 
drugs [97-101].  
Antimetabolites mirror native cellular building blocks. Many of them resemble nucleotides 
and nucleosides such as deoxycytidine, while others inhibit essential DNA synthesis enzymes 
such as methotrexate [91-101]. Nucleoside resembling antimetabolites can be incorporated 
within DNA during synthesis. This causes halting of the duplication of the DNA effected as 
the cellular machinery for replication can no longer bind to the non-native DNA [98].  
Methotrexate acts by inhibiting dihydrofolate reductase (DHFR), an enzyme which provides 
folate as an essential substrate for folate coenzymes and thus reduce purine synthesis 
dramatically. As purine synthesis is essential for DNA synthesis and replication, cell-cycle 
arrest or apoptosis may occur in response to the methotrexate. Antimetabolites are only 
effective when the cell is undergoing DNA synthesis in the S phase and thus are cell-cycle 
dependant in contrast to alkylating agents [98]. 
Other non-DNA base disrupting chemotherapy modalities include anti-microtubules, 
which act by disrupting microtubule formation, thus preventing mitosis [97,98]. These are once 
again cell cycle dependant as a cell must be entering a microtubule dependant phase of mitosis 
for the drug to be effective. Examples of anti-microtubules would be Vincristine, vinflunine, 
and paclitaxel [97-101]. There are also topoisomerase inhibitors, which act directly to inhibit 
topoisomerase I and II. Topoisomerase enzymes assist the partner strand of 
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replicating/transcribing DNA to supercoil, thus protecting its structural integrity during these 
processes. If these enzymes are inhibited by drugs such as irinotecan and novobiocin, the 
enzymes will not properly bind to DNA during these processes leading to increased DSB and 
SSB formation. The increase in DNA damage will lead to apoptosis in the affected cell. 
Topoisomerase inhibitors are non-cell cycle dependant [97-101].  Finally, we have the 
cytotoxic antibiotics. This class of chemotherapeutics consist of many groups including the 
anthracyclines, such as doxorubicin, and bleomycin [98]. The anthracyclines act by binding 
within two strands of DNA, thus disrupting their tertiary structure leading to instability. 
Bleomycin acts by binding to metal ions and producing free radicals which damage DNA.  
These therapeutics may act during multiple phases of the cell cycle [98].  
As is illustrated in the information above, cancer and the DDR are intricately 
connected. For a cell to become cancerous, its DDR must fail. As well, cancer cells use the 
DDR to their advantage by using it to repair their own DNA or by entering senescence to avoid 
apoptosis when it has been damaged by chemotherapeutics. Cancer cells want functional repair 
systems, but they also want lenient DDRs that will allow them to mutate rapidly, thereby 
avoiding and adapting to the immune system of their host. In this way, cancer plays a game of 
“cat- and- mouse” with the immune system and with its own repair system [97, 100-105, 112-
115]. 
 
1.3 AID/A3 enzymes play a potential role in tumor mutagenesis regulation and cancer 
initiation and progression 
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Tumor microenvironments contain high levels of oxidative radicals and alkylating species. 
The pH is often more acidic or basic than the surrounding tissue, meaning that DNA damage 
is more likely to be induced in these environments [88-115]. As previously stated, it has been 
shown that AID/A3 enzymes are highly expressed within tumors [2]. Their mutational 
signatures are prevalent in many different types of cancer tissue, indicating that these enzymes 
are involved in driving the process of cancer mutation and immune evasion. In addition, 
AID/A3 enzymes have been found to be active at sites where DNA is undergoing processes 
requiring single stranded exposure. A3A/B have been found to be active in replication forks, 
and at the free ends of DNA such as those found in DSBs and SSBs. A3A has been found to 
activate the DDR and cause cell cycle arrest as previously mentioned. Oxidative species and 
alkylative species cause the formation of DNA adducts that can ultimately result in SSBs or 
DSBs in DNA chains. Non-canonical bases such as 8oxoG are known to form lesions within 
DNA that evolve to G-quadruplexes [109-115]. It is known that the AID/A3 enzymes require 
a single-stranded area of DNA at least 5 bases in width to act [3-20]. Oxidative and alkylative 
damage could theoretically form lesions long enough within a chain of dsDNA, or at the ends 
in the case of helical breaks, whereby AID/A3 enzymes could interact with and mutate DNA. 
In addition to this, many chemotherapeutics act by disrupting the structure of singular 
nucleotides in the genome. It may be the case that AID/A3’s are active in the regions of 
chemotherapeutics, as chemotherapeutics often disrupt DNA tertiary structure and form single-
stranded regions. Many chemotherapeutics are cell-cycle specific, and thus only act during 
replication or mitosis [98]. These are the same moments of the cell cycle where AID/A3’s have 
been found to be active. Perhaps these enzymes are involved in recruiting repair machinery to 
areas which have been damaged by chemotherapeutics. In contrast, they may damage these 
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affected regions of DNA further and drive the process of cell cycle arrest and apoptosis. This 






Figure 1.2. Illustration of the complex interactions that may exist between 
AID/APOBEC3 enzymes and damaged DNA. AID/APOBEC3 enzymes interact with DNA 
in a destabilized state such as during replication. They act on DNA which is single-stranded. 
It can be surmised that they may act on DNA in single-stranded states during DNA damage 
and repair states such as those present in DSBs or SSBs. These ssDNA structure will be more 
present in cells experiencing stress such as those in oxidative/alkylated environments, radiation 
exposure, exposure to chemotherapeutics, and inflammation. These processes may lead to 
cellular senescence or tumorigenesis. Since ssDNA substrates are more actively present in cells 
experiencing these types of changes, it is reasonable to surmise AID/APOBEC3 enzymes may 
be active in these settings as well. The exact function of AID/APOBEC3 enzymes in these 
processes is unclear, but may be one of repair, cancer drive, activation of DDR, or a 
combination of these. The roles may change depending on whether the cells are cancerous or 
healthy functioning cells. The black arrows show the natural curse of how DNA-damaging 
enzymes may lead to cancer. The blue arrows suggest the large amount of interplay that may 
18 
 
exist between these processes and the uncertainty that exists within the current literature 
regarding the exact chronological order of these processes. 
 
1.4 Overall rationale 
Since both AID/A3 enzymes and oxidized/alkylated DNA adducts are more likely to be 
found within tumor microenvironments, and are indeed even induced through the use of 
chemotherapeutic drugs, it is reasonable to think that AID/A3 enzymes may encounter such 
damaged DNA quite frequently in tumor genomes [3-9, 15-20, 109-120]. If this is the case, 
then it is quite possible that oxidized, or alkylated, DNA adducts have a role to play in the 
activity levels and regulation of these enzymes within the tumor microenvironment. In a 
previous paper, it was shown that A3G localized to areas of DSBs within the nucleus [168,169]. 
A3G was shown to be required for the cells to mount a repair response, and this function was 
activity dependant [168,169].  It may be that the APOBECs enzymes play a previously 
undiscovered role in DNA damage and repair. Thus, the work described in this thesis was 
intended to be the first steps to deciphering whether DNA damage plays a role in the activity 
regulation of AID, A3A and A3B. We sought to examine whether bases damaged through 
alkylation or oxidation located proximal to the target dC could impact the catalytic activity of 







2. Materials and Methods 
 
2.1 Enzyme expression and purification 
Expression and purification of  Glutathione S-Transferase (GST) -AID has been previously 
described [53, 66, 79, 116].  Briefly, DE3 E. coli bearing the expression vector pGEX5.3 (GE 
Heathcare, USA) containing a GST-AID ORF were induced to express GST-AID using 1mM 
IPTG at 16°C for 16 hours. Cells were lysed using a French pressure cell press (Thermospectronic). 
The lysate was centrifuged and the supernatant was purified using Glutathione Sepharose high-
performance beads (Amersham) as per the manufacturer’s instructions. GST-AID was stored at -
80°C in 100mM NaCl, 20mM Tris-HCl pH 7.5, and 1mM dithiothreitol.  Purity of enzymes in 
demonstrated in the Coomasie stain shown in Figure 2.1. 
Expression and purification of A3A and A3B was carried out using a pcDNA3.1-based 
eukaryotic expression system, as described [36]. Briefly, EcoRV/KpnI-flanked human GST-A3A 
or GST-A3B ORF, each containing a single native intron, were inserted into the expression vector 
pcDNA3.1.  The insertion of the intron which is excised upon expression in the eukaryotic host, 
facilitated the construction of the expression vectors using standard bacteria-based cloning 
techniques. 25x 10 cm plates, each seeded with 5x105 HEK 293T cells, were transfected with 5 g 
of expression plasmid per plate using Polyjet transfection reagent (Froggabio). Cells were 
incubated for 48 hours, collected and resuspended in 500mM NaCl, 50mM Phosphate Buffer pH 
8.2, 0.2mM PMSF, and 50ug/ml RNAse A.  A3A and A3B expression was confirmed by western 
blotting using an anti-GST primary (Abcam) followed by secondary Goat anti-Rabbit IgG 
(SantaCruz). Cells were lysed using a French pressure cell press (Thermospectronic).  The Lysate 
was cleared by ultracentrifugation and the supernatant was purified using Glutathione Sepharose 
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high-performance beads (Amersham) as per the manufacturer’s instructions. GST-A3A and GST-
A3B was stored at -80°C in 100mM NaCl, 20mM Tris-HCl pH 7.5, 1mM dithiothreitol (DDT), 
5% Glycerol and 50ug/ml BSA. Yields and relative purity of the enzymes were assessed on 
Coomassie-stained SDS-PAGE using bovine serum albumin (BSA) standard curves, as previously 
described [69,83]. Briefly, known quantities of purified protein in solution were loaded onto an 
8% Acrylamide/SDS resolving gel along with known concentrations of BSA. Once electrophoresis 
was complete, The gel was imaged using Imagequant software and Kodak Imaging Hardware. 
Relative quantification of each purified protein was done by comparing the band density of the 
purified protein to band density of known concentrations of BSA. Relative Quantification was 
done using three bands of purified protein and 5 concentrations of BSA as shown in Figure 2.1. 
 
Figure 2.1. GST-AID, GST-A3A, and GST-A3B expression and purification. A. 
Representative Coomassie-stained protein gel of purified GST-tagged A3A, A3B, and AID. A 
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sample of each purified protein was loaded next to a range of BSA standards used for quantification 
of enzyme concentrations. 
 
2.2 Preparation of damaged and non-damaged oligonucleotide substrates 
Single-stranded and partially single-stranded bubble oligonucleotide substrates for AID, 
A3A and A3B enzyme assays were prepared as described previously [53, 66, 79, 116]. Briefly, 
DNA oligonucleotides containing normal and damaged nucleotides (Figure 2.2) were synthesized 
and HPLC purified (Integrated DNA Technologies, Midland, Trilink). 2.5 pmol of the 
oligonucleotide bearing the target dC was 5’-labelled with [-P32] dATP using T4 polynucleotide 
kinase (New England Biolabs). After labeling, oligonucleotides were purified using mini-quick 
spin DNA columns (Roche) and either diluted in TE buffer to 50 fmol to generate single-stranded 
substrates or annealed with 2-fold excess bottom strand in TE buffer containing 100 mM KCl to 
generate the bubble substrates.  Annealing was carried out through slow cooling from 96°C to 4°C 
at the rate of 1°C/min.  Formation of bubble substrates was verified by electrophoresis on 8% 
acrylamide native gels alongside unannealed labeled ssDNA oligonucleotides.  The designation of 
substrates which have been described previously [36, 53, 66, 79, 116] indicates their shape and 
target motif sequence. For instance, Bub7TGC is a bubble type substrate containing a 7-nucleotide 
long ssDNA region with the target WRC motif TGC. Substrates were concentrated up to 500 
fmol/µl using a standard speed vacuum apparatus, followed by serial dilution 250, 100, 75, 50, 40, 








Figure 2.2. Oxidized and alkylated bases and substrates. A. List of all damaged bases used in 
this study. From left to right, name of each base, the base chemistry relative to the normal version, 
and a brief description and rationale for selection. The brief statements on the attributes of each 
base are summarized from cited references (91,92, 95-114, 117-119,128, 136, 147). B. Standard 
bubble and single-stranded substrates used in the alkaline cleavage deamination assay. The upper 
panel shows an example of the partially single-stranded (bubble) substrates used for testing the 
enzymatic activity of AID, and the lower panel shows fully single-stranded substrates used for 
testing the activities of A3A and A3B.  The catalytic efficiency of each enzyme on substrates 
containing the damaged base (denoted by “X”) in the -1 or -2 position (right panels) was compared 
against a control substrate that is identical except for containing the normal undamaged version of 
the same base in the same -1 or -2 position (left panels).   
 
2.3 Alkaline Cleavage Deamination Assay 
The standard alkaline cleavage assay to measure the catalytic activity of AID/APOBECs 
has previously been described [53, 64, 66, 79, 116]. Briefly, deamination reactions consisted of 
1µl of substrate at a substrate concentration ranging from 0.1-10 nM, 6µl reaction buffer (100mM 
phosphate buffer pH 7.2 for AID, HEPES pH 5.5 for A3A and A3B), and 3µl enzyme (2-10 ng) 
in a total reaction volume of 10 µl.  For initial determination of enzyme activity on normal vs. 
damaged substrates, a substrate concentration of 2-5 nM was used. For measurement of catalytic 
efficiency kinetics (Kcat, Km) a range 0.15-100 nM substrate concentrations were used for 
incubations with AID/A3A/A3B for lengths of time that were determined through time course 
kinetics (Figure 2.3) to represent the initial velocity phase of the deamination reaction for each 
enzyme (60 minutes for A3A/A3B, 120 min for AID). Following the AID/A3A/A3B incubation 
with substrates, AID/A3A/A3B were heat-inactivated by incubation at 80°C for 20 minutes.  The 
reaction volume was then doubled to 20 µl by the addition of Uracil-DNA-Glycosylase (UDG; 1 
µl containing 1 unit), 2 µl 10x UDG buffer (New England Biolabs), and 7 µl ddH2O, then incubated 
at 37°C for 30 minutes to excise deaminated dC’s (dU’s). Finally, 100mM NaOH was added to 
the reaction mixture which was incubated at 96°C for 5 minutes to cleave the abasic site left as a 
24 
 
result of dU excision. Each sample was loaded on 14% (for AID) and 16% (for APOBEC3’s) Urea 
denaturing Polyacrylamide gels for electrophoresis. Gels were exposed to a Kodak Storage 
Phosphor Screen and visualized using a phosphorimager (Bio-Rad).  
Figure 2.3. Representative time-course kinetics to determine the initial velocity phase of 
enzyme incubation. Representative time course alkaline cleavage assays of AID (Upper Left), 
APOBEC3A (Upper Right) and APOBEC3B (Lower Left). Graphs show representative assays for 
two substrates (one bearing a damaged base, and the corresponding control bearing the normal 
base version) for each enzyme: Bub7TGC/Bub7T(8oxoG)C for AID, and ssATC/ssT(8oxoG)C 
for A3A and A3B. Incubation lengths within exponential catalytic phase of each enzyme/substrate 





2.4 Data Collection and Michaelis-Menten Enzyme Kinetics Analysis 
Data collection and analysis were performed as previously described for the alkaline 
cleavage deamination kinetics assay [36, 42, 64, 66]. Briefly, each enzyme kinetics experiment 
was carried out using 3 preparations of each of AID/A3A/A3B, purified independently but in 
parallel. Within each experiment, each enzyme:substrate reaction was carried out in triplicate and 
each triplicate gel lane was analyzed twice independently using the Quantity One 1-D Analysis 
Software (Bio-Rad) to conduct band densitometry of the substrate and product bands.  Using this 
methodology, the damaged and normal control substrate pairs were always tested in parallel.   Data 
were graphed using GraphPad Prism software and error bars represent standard deviation.  Km 
and Vmax values were obtained by the non-linear regression Michaelis Menten analysis in 
Graphpad and used to derive Kcat based on the concentration of enzymes used. 
 
2.5 Computational prediction of AID/A3A/A3B surface interactions with damaged bases 
Docking of DNA substrates with AID, A3A, and A3B was performed as previously 
described [64, 65].  Briefly, for AID we used a recently crystalized truncated AID variant (PDB: 
5W0U, 5W0R, 5W1C) and a previously-described functional structure of native full-length AID 
obtained by a combined computational-biochemical method [64]. This functional structure of the 
AID has been verified by the recent X-ray crystallography studies of partially truncated/mutated 
AID variants [64, 65, 117, 118]. For A3A, we used 3 recently-published structures: Human A3A 
X-ray (PDB: 4XXO) [119], Human A3A X-ray (PDB: 5SWW:3.A) [56], Human A3A NMR 
(PDB: 2m65) [46]. For A3B, we utilized several conformations of the NMR structure of the A3B-
CD2 (PDB: 2NBQ) [120]. Using PyMOL we defined catalytic pocket accessibility by ascertaining 
whether the catalytic glutamate was exposed to the surface of the protein and if the conformation 
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was able to dock a dC in deamination-feasible conformations as previously described [64].  To 
examine the interactions of ssDNA substrates containing the oxidized or alkylated bases with the 
surface of AID and A3A we used SwissDock (http://www.swissdock.ch) to ascertain the most 
energetically favorable conformations of the substrate across the protein surface [121, 122].  The 
creation of substrates began with using ChemDraw Prime v.16.0 
(http://www.cambridgesoft.com/software/overview.aspx) to initially make the 2D version of the 
substrate, and continued with Marvin Sketch v.5.11.5 
(http://www.chemaxon.com/products/marvin/marvinsketch/) to assemble it into 3D.  SwissParam 
(http://swissparam.ch) was then used to generate the docking parameters [123].  These substrates 
were created with a ssDNA template (5’-TTNNNTT’-3) where the central “NNN” motif was either 
AGC, TGC, or TTC as normal controls.  For damaged DNA, dA in AGC was replaced with (8-
Oxo-dA) or (1-Me-dA), while dT or dG in were replaced with (O4-Me-T), (8-Oxo-dG) or (O6-Me-
dG).  UCSF chimera v.1.11.2 (https://www.cgl.ucsf.edu/chimera) was used to view substrate 
interactions with AID, A3A and A3B [124].  For each docking simulation, 256 lowest energy 
binding modes divided into 32 low-energy clusters were created. Furthermore, each 
enzyme:ssDNA binding simulation was carried out multiple times to create 1728 clusters (13824 
binding modes) for AID, 5600 clusters (44800 binding modes) for A3A, and 3840 clusters (30720 
binding modes) for A3B-CD2. Molecular docking simulations were then qualitatively and 
quantitatively analyzed to examine the interactions with the damaged bases in the -2 or -1 








3.1 Selection of damaged bases and experiment design 
The experimental design for comparing AID/A3A/A3B activity on damaged vs. normal 
substrates is illustrated in Figure 2.2. For damaged bases, we selected 8-oxo-7,8-dihydro-2’-
deoxyguanosine (8oxoG), 8-oxo-2’-deoxyadenosine (8oxoA), O6-Methyl-deoxyguanosine 
(O6MeG), O4-Methyl-deoxythymidine (O4MeT), and 1-Methyl-deoxyadenosine (1MeA). 8oxoG 
and 8oxoA are the two most common damaged bases in the human genome, because the 8th prime 
carbon active group of purine bases is easily oxidized due to its low redox potential (Figure 2.2A) 
[125-129]. Amongst the four bases, dG is most susceptible to oxidation [127-130], making 8oxoG 
the most common oxidized base form in the human genome and frequently used as a marker of 
genome senescence [126, 131-134]. O6-Methyl-deoxyguanosine (O6MeG) and O4-Methyl-
deoxythymidine (O4MeT) were chosen because they are two frequently found alkylated bases. 
Alkylation involves addition of alkyl moieties to the ring nitrogen or the exocyclic oxygen by N-
nitroso compounds such as the nitrosamines in tobacco smoke [135-137]. O6MeG is one of the 
most common and toxic forms of DNA alkylation, formed by carcinogenic compounds such as 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) [135, 138, 139]. O4MeT was selected as 
another example of alkylation. O4MeT is produced less frequently than O6MeG, but is a more 
potent source of mutation [138, 140]. 1-Methyl deoxyadenosine (1MeA) is a common alkylated 
base that is generated by the transfer of a methyl group to the N1 nitrogen atom of deoxyadenosine 
and can cause critical replication termination [141-144]. Additionally, these damaged bases were 
chosen due to their clinical relevance, as they are known to be induced in cancer genomes by 




Although AID and A3s exhibit some local sequence specificity beyond the -2/-1 bases that 
can sometimes include the +1 base [56], the impact of these base positions are generally less than 
that of the -2/-1 bases. Recently, it has been speculated that the +1 base plays a role in intra-DNA 
interactions with the -2 nucleotide to conform the U-shape of the substrate. These bases can bind 
to the enzyme surface as either a purine or a pyrimidine but the -1 and -2 nucleotides play a more 
prominent role for specificity from [146, 147]. Thus, here we focused on the effect of the -2/-1 
base positions. To determine if the aforementioned oxidized or alkylated damaged bases impact 
the deamination of their neighbouring dC by AID, A3A and A3B, we incorporated them into the 
-2 and -1 positions relative to the target dC in ssDNA substrates. These substrates have been shown 
to be optimal targets for deamination activities of these purified form enzymes (Figure 2.2B).  A 
7 nucleotide-long ssDNA bubble region was selected as the substrate for AID because amongst a 
panel of different ssDNA forms, this bubble form was found to be the favored substrate for AID 
[42, 51].  An unpaired single-stranded DNA substrate was used for A3A and A3B since it has been 
shown to be the optimal substrate for detecting the in vitro activity of these enzymes [46, 60, 61].  
As a control for each substrate with a damaged base in the -2 or -1 positions, we tested in 
parallel an identical substrate bearing the corresponding normal base in the same position (Figure 
2.2B, left vs. right panels). For instance, substrates with 8oxoA in the -2 position which compose 
the motif (8oxoA)GC were tested in parallel with control normal substrates containing AGC. We 
tested the catalytic efficiencies of purified AID, A3A, and A3B on substrates bearing the five 
alkylated or oxidized bases in the -2 or -1 positions relative to the target dC. To measure relative 
catalytic efficiencies we used the alkaline cleavage assay to determine deamination rates, as this 
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is the standard assay that has been widely used to measure the biochemical parameters and 
substrate preferences of AID/A3 enzymes [51, 53, 79, 80, 148]. 
3.2 AID can deaminate deoxycytidines neighbouring certain oxidized or alkylated bases 
with efficiency comparable to native WRC motifs 
 To evaluate the relative efficiency of AID on substrates bearing damaged bases, we 
compared initial deamination velocity kinetics of purified AID between substrates containing 
damaged bases in the -2 or -1 position and control substrates bearing the normal base version in 
the equivalent position. We first performed time course deamination kinetics experiments to 
determine enzyme:substrate incubation times for each of the three enzymes (AID, A3A, and A3B) 
that would be within the initial velocity phase for Michaelis-Menten kinetics (Figure 2.3). To 
ensure that incubation periods for all substrates fell within the initial velocity phase of the 
deamination reaction time course kinetics were performed on oligos containing a preferred hotspot 
sequence motifs of each enzyme and an oligo with a damaged base: TGC/T(8oxoG)C for  AID 
and ATC/T(8oxoG)C for A3A/A3B.  Catalytic kinetics were then conducted on a range of 
substrate concentrations using these incubation times to compare initial velocity kinetics on 
substrates bearing damaged bases with that of control substrates bearing the normal base in the 
same position (Figure 2.2B).  From the data, catalytic parameters (Km, Kcat, Vmax) were 
determined for each enzyme:substrate pair, and differences in the catalytic efficiency between 




Table 1. Catalytic parameters/ fold difference of activity of AID, APOBEC3A and APOBEC3B on 
damaged base motifs compared to normal favored sequence motifs.  
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We found that AID was capable of deaminating all damaged trinucleotide motifs that were 
tested. When the initial velocity of AID activity was compared between damaged and non-
damaged control substrate pairs, there was a general trend of robust and comparable deamination 
of damaged motifs (Figure 6B).  Kcat/Km ratios shown in Table 1 (top section: AID) revealed that 
T(8oxoG)C was deaminated with lower efficiency than the control WRC motif TGC (1.8 x 10-4  
vs. 5 x 10-4) while T(O6MeG)C was deaminated with comparable catalytic efficiency (4.8 x 10-4  
vs. 5 x 10-4) and (O4MeT)GC was deaminated with  higher efficiency (8.4 x 10-4  vs. 5 x 10-4).  
(1MeA)GC was deaminated by AID with lower efficiency than the control undamaged WRC motif 
AGC (2.6 x 104  vs. 4.2 x 10-4) whilst (8oxoA)GC was deaminated with increased efficiency (7.7 
x 104  vs. 4.2 x 104). Of the five damaged base-containing substrates tested, one supported 
comparable deamination efficiencies to its normal control WRC-containing and two were 
deaminated with higher catalytic efficiency. It is noteworthy that all Kcat/Km ratios of AID’s 
deamination of damaged base motifs fell within a relatively comparable 3-fold range of 
undamaged control WRC controls, considering that AID’s preference for normal undamaged 
WRC vs. non-WRC motifs has been shown to fall within a 3- to 6-fold range using the same assay 
and substrates employed here, this indicates that AID can efficiently deaminate all tested damaged 
motifs [42, 50, 53, 66, 149]                                                                 
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Figure 3.1. AID deaminates substrates with damaged bases at efficiencies nearing that of 
native WRC motifs. A. Representative enzyme kinetics measuring the initial velocity kinetics of 
AID deamination of a native WRC motif (Bub7TGC, a seven nucleotide-long bubble substrate 
containing the motif TGC; left panel), as compared to its damaged motif counterpart bearing the 
most commonly damaged form of dG 8oxoG in the equivalent (-1) position (Bub7T(8oxo)GC, a 
seven nucleotide-long bubble substrate containing the motif T(8oxoG)C; right panel), over a range 
of [Substrate] from 0.15 to 50  nM. Bub7 connotates the seven nucleotide-long bubble substrate 
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used for AID assays. The negative control reaction “Neg” is a no enzyme control that contains 
buffer in place of AID and is otherwise treated in the same manner with UDG and alkaline 
cleavage.  B. Enzyme kinetics of AID-mediated deamination for each damaged base substrate are 
compared to the control substrates tested in parallel which contain the undamaged native 
counterpart base in the same -2 or -1 positions; top left: Bub7T(8oxo)GC vs. Bub7TGC, top 
middle: Bub7T(O6MeG)C vs. Bub7TGC, top right: Bub7(O4MeT)GC vs. Bub7TGC, bottom left: 
Bub7(8oxoA)GC vs. Bub7AGC, bottom right:  Bub7(1MeA)GC vs.  Bub7AGC. On each graph, 
the open symbol represents the substrates containing the damaged base whilst the filled symbol 
represents the control substrate containing the normal undamaged version of the same sequence 
motif.  
 
3.3 A3A deaminates deoxycytidines in oxidized or alkylated motifs with comparable or 
modestly higher efficiency than normal DNA 
 We then tested the activity of purified A3A on substrates bearing oxidized or alkylated 
bases. Figure 5A shows an example of A3A’s catalytic kinetics for the damaged motif T(8oxoG)C 
compared to its undamaged control counterpart, the TGC motif.  Like AID, A3A was active on all 
tested damaged base motifs (Figure 7B).  Kcat/Km ratio analyses (Table 1 middle: A3A) revealed 
that T(8oxoG)C supported an increase in catalytic efficiency when compared to its control 
undamaged substrate TGC (0.078 vs. 0.060) whilst T(O6MeG)C exhibited a decrease (0.041 vs. 
0.060).  T(O4MeT)C demonstrated reduced catalytic efficiency compared to the favored normal 
YC motif TTC (0.060 vs. 0.11). T(8oxoA)C supported an increase in catalytic efficiency when 
compared to the undamaged control TAC (0.069 vs. 0.045).  Of the damaged forms of the favored 
natural YC motif ATC, (1MeA)TC displayed a comparable catalytic efficiency (0.13 vs. 0.14) 
whilst (8oxoA)TC supported an increase (0.18 vs. 0.14).   
Consistent with its demonstrated YC motif preference [46, 56, 58, 80, 83, 148] amongst 
the four normal control motifs tested, A3A exhibited its highest catalytic efficiencies on TTC and 
ATC.  Remarkably, of the six damaged base motifs tested, two ((1MeA)TC and (8oxoA)TC) were 
deaminated by A3A with catalytic efficiencies comparable or modestly exceeding that of both of 
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these most favored normal YC motifs, whilst another two (T(8oxoG)C and T(O6MeG)C) 
supported catalytic efficiencies that were modestly higher than their own corresponding control 
undamaged non-YC motifs.  
  To ensure that the observed deamination preferences for damaged base motifs over their 
normal control substrates reflect a bona fide enzymatic property of the deaminases tested, we 
conducted an additional control experiment. Since the alkaline cleavage assay for deamination 
relies on dU excision by Uracil DNA glycosylase (UDG) after dC to dU deamination in the 
AID/A3:substrate incubation phase, we sought to formally ensure that the more robust product 
formation on damaged motifs was not due to a sequence preference for the damaged motif at the 
dU excision stage, though it is known that dU excision by UDG in the context of the alkaline 
cleavage dC deamination assay is not subject to a local sequence preference. To this end, we 
incubated dU-converted versions of a normal and damaged substrate pair with UDG and observed 
no difference in the efficiency of dU excision, and no product in the absence of UDG, as expected 
(Figure 8). This indicates that the preferences measured in the alkaline cleavage assay reflect the 









Figure 3.2. APOBEC3A deaminates substrates with certain damaged bases more efficiently 
than native sequence motifs.  A. Representative enzyme kinetics measuring the initial velocity 
kinetics of A3A deamination of a damaged and undamaged pair of motifs (ssT(8oxoG)C vs.. 
ssTGC; right panel) over a range of [Substrate] from 0.15 to 50  nM.  The negative control reaction 
“Neg” is a no enzyme control that contains buffer in place of A3A and is otherwise treated in the 
same manner with UDG and alkaline cleavage.  B. The initial velocities of A3A mediated 
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deamination for each damaged base substrate are compared to the control substrates tested in 
parallel which contain the native normal counterpart base in the same -2 or -1 positions relative to 
the target dC.; top left: ssT(8oxo)GC vs.vs. ssTGC, top middle: ssT(O6MeG)C vs. ssTGC, top 
right: ss(8oxoA)TC vs. ssATC, bottom left: ss(1MeA)TC vs. ssATC, bottom middle: ssT(O4MeT)C 
vs. ssTTC, bottom right: ssT(8oxoA)C vs. ssTAC. On each graph, the open symbol represents the 
substrates containing the damaged base whilst the filled symbol represents the control substrate 
containing the normal undamaged version of the same sequence motif.  
 
 
Figure 3.3. Difference in deamination of TGC and T(8oxoG)C is not due to Uracil-DNA 
Glycosylase. Comparison of uracil excision activity of UDG on the control substrates TGU vs. 
T(8oxoG)U (Left panel) to demonstrate equivalent UDG activity on both substrates. A 
representative alkaline cleavage gel depicting the percent excision product produced by the 
incubation of UDG with 5 nM of GU or (8oxoG)U substrate (right panel). 
 
 
3.4 A3B can deaminate deoxycytidines located in damaged base motifs with higher 
efficiency than normal DNA 
 Figure 7A shows A3B’s initial catalytic kinetics on the damaged motif T(8oxoG)C 
compared to its undamaged control counterpart, the TGC motif.  As with AID and A3A, A3B also 
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exhibited robust deamination activity on the tested damaged motifs (Figure 9B).  Kcat/Km ratio 
analyses revealed that like A3A, A3B also deaminated T(8oxoG)C with higher catalytic efficiency 
than its undamaged counterpart TGC (0.38 vs. 0.30), whilst  T(O6MeG)C was deaminated with 
comparable catalytic efficiency (0.32 vs. 0.30). T(O4MeT)C was deaminated by A3B less 
efficiently than its undamaged YC motif control TTC  (0.20 vs. 0.42). On the other hand, A3B 
deaminated T(8oxoA)C with higher catalytic efficiency as compared to its undamaged control 
substrate TAC (0.59 vs. 0.20). (8oxoA)TC was deaminated with higher catalytic efficiency than 
its undamaged YC control ATC motif (0.79 vs. 0.49) while (1MeA)TC was deaminated with 
comparable efficiency (0.48 vs. 0.49).     
As expected from its favoring of YC motifs, amongst the normal motifs tested, TTC and 
ATC exhibited the highest Kcat/Km ratios (0.30 and 0.49, respectively).  Of the six damaged base 
motifs tested, four were favored by A3B over their own undamaged control substrates. 
Remarkably, of these four damaged motifs, two (T(8oxoA)C and (8oxoA)TC) were deaminated 
by A3B even more efficiently, and two (T(8oxoG)C and (1MeA)TC) with comparable efficiency, 




Figure 3.4. APOBEC3B deaminates substrates with certain damaged bases more efficiently 
than normal motifs. A. Representative enzyme kinetics measuring the initial velocity kinetics of 
A3B deamination of an undamaged motif (ssTGC; left panel), as compared to its cognate damaged 
motif (ssT(8oxoG)C; right panel), over a range of [Substrate] from 0.15 to 100 nM. The negative 
control reaction “Neg” is a no enzyme control that contains buffer in place of A3B and is otherwise 
treated in the same manner with UDG and alkaline cleavage.  B. The initial velocities of A3A 
mediated deamination for each damaged base substrate are compared to the control substrates 
tested in parallel which contain the native normal counterpart base in the same -2 or -1 positions 
relative to the target dC. Top left: ssT(8oxo)GC vs. ssTGC, top middle: ssT(O6MeG)C vs. ssTGC, 
top right: ss(8oxoA)TC vs. ssATC, bottom left: ss(1MeA)TC vs. ssATC, bottom middle: 
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ssT(O4MeT)C vs. ssTTC, bottom right: ssT(8oxoA)C vs. ssTAC. On each graph, the open symbol 
represents the substrates containing the damaged base whilst the filled symbol represents the 
control substrate containing the normal undamaged version of the same sequence motif.  
 
3.5 In silico analysis of interactions between the catalytic regions of AID, A3A and A3B with 
damaged bases 
 We previously presented AID-DNA docked complexes wherein we highlighted several 
DNA binding residues and secondary catalytic residues that stabilized dC in the catalytic pocket 
[64].  Our analysis revealed that the majority of high-frequency DNA binding residues were 
localized to four secondary catalytic loops: loops 1, 3, 5 and 7 (L1, L3, L5 and L7, respectively). 
Furthermore, L7, and to a minor extent L1, have been shown to mediate substrate-specificity 
amongst the AID/APOBEC family [54, 67].  Here, we focused on -1 and -2 base interactions based 
on previous studies on interactions of AID/APOBECs with ssDNA, the majority of -1 and -2 base 
binding interactions is likely to  be localized to these secondary catalytic loops, with emphasis on 
L1 and L7 [54, 56, 57, 61, 64, 117, 150-152].  Examining -1/-2 nucleotide positioning in the 
catalytic region, we observed in certain conformations of AID, the interface between L1 and L7 
formed a specificity pocket that frequently bound a purine base from either the -1 or -2 position of 
TGC or AGC substrates. This finding corroborated previous findings that demonstrated L7 and to 
a minor extent L1 mediating substrate specificity in AID [54, 55, 67]. The L1/L7 specificity pocket 
contains a minor contribution from L1 (A21, R24), L5 (W84) and loop 12 (L198) with the majority 
of residues from L7 (L113, Y114, F115, C116, E117).TGC formed the majority of interactions 
with L1 and L7, specifically within the specificity pocket described above. In contrast to TGC 
binding, T(8oxoG)C showed an increase in interactions with L1 but a decrease with L7, 
corresponding to more interactions with A21 and R25 in L1 and decreased interactions with F115, 
C116, E117 and D118 in L7. When each damaged base was examined alongside the normal control 
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base in the same position, we found that increased/decreased catalytic activity were associated 
with increased/decreased predicted interactions with L7, respectively. These analyses suggest that 
L7 and the L1/L7 interface acts as an anchoring point that stabilizes purines from the -1 and -2 
positions, thereby selecting for more catalytically productive AID-DNA complexes (Figure 10A, 
Figure 11). 
In the case of A3A, the damaged motifs that had the most pronounced catalytic effects were 
in the -1 position. Normal dG in the -1 position was predicted to form many interactions with L5 
and L7 on planar and negative residues while 8oxoG in the -1 position interacts largely with L3 
on planar and non-charged polar residues. This is seen as a shift from residues F102, and Y132, 
along with several weaker interactions in L5/L7, towards multiple interactions on Q58, A59, N61, 
L62, and G68 of L3.  This predicted trend of decreased L5/L7 interactions and increased L3 
interface usage was consistent across the damaged bases interacting with the surface of A3A. A3B-
CD2 exhibits a small extension of 3 such that F285 and W287 and L318 from 4 juxtapose to 
form a shallow hydrophobic side-pocket. Our docking analysis of A3B-CD2 with TGC showed 
that when dC was bound in the catalytic pocket, the majority of conformations had the -1 dG of 
TGC pi-stacked with F285 and W287 along with minimal contact with L318. When comparing 
T(8oxoG)C, we observed less complexes with 8oxoG bound in the F285/W287/L318 shallow 
hydrophobic side-pocket. The largest difference involved increased 8oxoG binding to L1 and 
decreased binding to 4 which corresponded to binding in the L1/L7 region of the ssDNA binding 
groove (Figure 11C), where the 8oxoG pi- stacked with Y315 and hydrogen bonded from the 
peptide backbone of R210 and R212 as well as from the side-chains of R211, Y313 and Y315 








Figure 3.5. Surface regions of AID, A3A and A3B are predicted to interact robustly with 
damaged bases. AID (A), A3A (B) and A3B (C) were docked with normal and damaged 
substrates to examine interactions.  Shown are representative analyses of interactions of the 
catalytic pockets and surrounding regions of AID/A3A/A3B with TGC (Left Panels), and 
T(8oxoG)C (Right Panels). Residues frequently involved in nucleotide interactions are denoted. 
Negative and positively charged residues are colored red and blue respectively while purple 
represents the catalytic pocket residues.  The DNA substrate is denoted by the colours yellow, 
green, and cyan which respectively represent the main DNA chain, the cytidine in the catalytic 
pocket, and the undamaged nucleotide (-1 dG of TGC; Left Panels) compared to the damaged 



















Figure 3.6. Distribution of the predicted interactions between damaged base-containing 
substrates and surface regions of AID, A3A and A3B. AID (A), A3A (B), and A3B (C) were 
docked with normal and damaged substrates to visualize substrate:enzyme interactions. Each of 
these pie charts represent the percent interactions of the nucleotide of interest from a 7 nucleotide-
long DNA sequence docked on the surface of each enzyme. These sequences contain either a 
damaged nucleotide in the -1 or -2 position or the undamaged normal form of the same base while 
the deoxycytidine which enters the catalytic pocket is underlined. 
 
When comparing catalytic activities between other damaged bases and their undamaged 
controls for A3A and A3B, there was a general structural trend that was in line with the catalytic 
activity data. We found that T(8oxoG)C, T(8oxoA)C and (8oxoA)TC all showed an increase in 
catalytic activity relative to their control oligos  (Table 1). All oxidized motifs showed an increase 
in interactions with L1 and L3 and/or a decrease in interaction with L5 and L7 (Figure 11). In 
contrast, the damaged motifs that resulted in lowered catalytic activities ofA3A and A3B resulted 
in a similar or greater number of interactions with L1 and L3, but increased interactions with L7. 
These data suggest that damaged bases -1 or -2 upstream from the target dC that bind more often 
with L3 or the L1/L3 interface result in a higher catalytic activity. The only exception was 
T(O6meG)C, which showed an increase on L1/L3 interactions and decreases on L5/L7 
interactions, yet exhibited no change in catalytic activity. This is potentially due to the lingering 
4 interactions present for A3B and L7 binding for A3A compared with the oxidized -1 










Although the activities of AID/A3s have been measured on a variety of modified (eg. 
methylated, oxidized) dC targets, the impact of damaged bases surrounding the target dC has not 
been studied. To this end, we measured the activity of purified AID, A3A, and A3B on substrates 
containing several of the most commonly occurring damaged bases proximal to the target dC. 
Overall, the Michaelis Menten catalytic parameter values determined here for AID, A3A, and A3B 
were consistent with previous studies, and as established the latter two enzymes exhibited catalytic 
rates significantly faster than the relatively lethargic AID [46, 53, 65, 80, 153].  We observed that 
dC positioned proximal to these damaged bases are efficiently deaminated by AID, A3A and A3B, 
and are sometimes even favored, by several fold in terms of catalytic efficiency, over their native 
motifs.  For instance, when 8oxoA and 8oxoG, two of the most abundant damaged purines in the 
human genome were placed upstream of the target dC, the catalytic efficiency of A3A and A3B 
increased compared to the undamaged control sequence, reaching even higher levels than their 
most preferred normal YC motif. Thus, we conclude that these enzymes have the inherent catalytic 
ability to deaminate certain damaged DNA motifs even more efficiently than their most favored 
sequences yet characterized which consist of normal undamaged WRC or YC motifs.  
When binding the -1 nucleotide of TGC, AID, A3A and A3B all form numerous 
interactions with L7 and adjacent regions. In AID, the -1 dG nucleotide of TGC binds in the L1/L7 
interface (Figure 4C). Due to large structural differences between AID and A3A/A3B, especially 
at this L1/L7 interface, we found A3A preferred the L5/L7 interface, while A3B bound in a similar 
region, the L5/α4/L7 interface.  Thus, binding of the -1 dG nucleotide of TGC is accomplished 
through several interactions between L7 in conjunction with neighboring surface regions, dictated 
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by structural differences between AID, A3A and A3B. Interestingly, interactions formed by the      
-1 8oxoG nucleotide interactions of T(8oxoG)C also differed amongst the three enzymes:AID 
bound predominantly with L1, A3A with L3 and A3B with the L1/L7 interface. Comparing the 
TGC binding with the L5/L7 interface of A3A and the L5/α4/L7 interface of A3B, we found two 
conserved residues involved: F102 and F285 from A3A and A3B, respectively, as well as L135 
and L318 from A3A and A3B, respectively.  In agreement with our findings, a structural analysis 
of A3A found that both F102 and L135 from L5 and L7, as well as several residues in L3 displayed 
large chemical perturbations upon binding ssDNA [154]. Additionally, it was also discovered that 
the mutation of F102A, L135A, as well as several L3 residues in A3A lowered catalytic activity 
but did not completely abrogate it, suggesting these regions are important to fine-tuning catalytic 
rates in A3A. Because these regions are involved in binding TGC and T(8oxoG)C, our data suggest 
that the change in interaction with these regions is responsible for the change in catalytic activity 
on these substrates.  This is especially interesting when considering the homology of L1, 3, 5 and 
7 amongst AID, A3A and A3B. AID has a shortened loop, thus forming different interactions 
depending on the substrate [65]. A3A/A3B on the other hand have an extended L3 (8 amino acids 
longer), which extends outwards from the protein core [56, 147]. Besides the role in secondary Zn 
coordination [59], L3 also plays a role in ssDNA binding and, from our data, -1/-2 nucleotide 
interactions with damaged bases. A3A and A3B have 100% identity for L5 and L7, but have near 
identical homology in the L3 region, except for one amino acid (Q58 in A3A, E241 in A3B). 
However, the impactful difference appears to reside in L1 which is very different and extended in 
A3B as compared to A3A. This might explain the differences inT(8oxoG)C binding and activity  
between A3A vs A3B where the L3 surface is more suitable for binding in A3A, while the L1/L7 
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interface is more suitable in A3B.   
A3 enzymes and AID bind ssDNA substrates which attach to one or two surface grooves 
in a generally U-shaped manner, with bases that can be flipped to contact the enzyme surfaces and 
interact with L1, 3, 5, and 7 [46, 56, 57, 64, 65, 117, 146, 155, 156]. Our substrate docking 
predictions were consistent with this surface binding mode (Figure 10) and also in line with the 
robust activity of all three enzymes on the oxidized and alkylated motifs, suggested that all three 
can bind these motifs on their surface in manners that form contacts between the -1 and -2 damaged 
bases with the substrate specificity loop (L7) and adjacent regions (L1, L5, L3, 3, 4) (Figure 
11). These in silico observations require definitive confirmation by experimentally examining the 
enzyme structures bound to damaged vs normal DNA motifs. Nevertheless, the docking 
predictions support the enzyme assay data showing all three enzymes have the inherent structural 
capacity to efficiently and specifically recognize and act on damaged base motifs.   
Our in vitro enzyme assay data indicate that beyond AID/A3 enzymes instigating DNA 
damage, their catalytic efficiencies can be increased by pre-existing DNA damage proximal to a 
target dC. AID/A3 enzymes access their genomic targets through various cellular processes that 
generate ssDNA (bubbles, forks, branched structures). Although we have not examined genome-
wide targeting, our data suggests that if AID, A3A, or A3B encounter damaged base motifs through 
the aforementioned cellular targeting mechanism, they would have the catalytic capacity of 
deaminating some of these substrates even more efficiently than normal DNA. Under normal 
conditions, natural oxidization/alkylation events in the genome are repaired with high efficiency, 
decreasing the likelihood that AID/A3A/A3B will encounter these occurrences. However, DNA 
damage repair deficiencies are prominent in cancers [105, 157-159]. For instance, 8oxoG which is 
the most prevalent form of oxidized DNA damage in the genome often causes G:A mismatches 
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within a cellular genome due to its pyrimidine-like behavior [109, 160], which also correlates with 
our observation of its favorability for A3A/B as a  -1 position base where a pyrimidine is highly 
favored. 8oxoG:A is typically repaired with high-fidelity in human genome by the glycosylase/AP 
lyase OGG1 which excises 8oxoG from the DNA duplex or by MYH which removes dA from the 
8oxoG:A pair; however, these repair pathways can be perturbed in cancer [109, 161]. O6-
methylgaunine (O6meG), which often results from environmental alkylating DNA damage, can 
be repaired by O6-alkylgaunine-alkyltransferase (MGMT); however, akin to 8oxoG, high levels 
of O6meG mutations are also found within several different types of cancer cells [108, 115]. 
Indeed, the most widely used types of chemotherapeutics are also sources of overburdening DNA 
alkylation and oxidation due to potent compounds [93, 94, 111, 126-128, 137, 145].  In addition, 
DNA oxidative damage such as 8oxoG and 8oxoA often lead to the stalling of transcriptional 
elongation, potentially exposing oxidized ssDNA regions known to be targets of AID/A3 enzymes 
[43, 162]. Oxidation and alkylation of DNA can also induce blockage of replicative polymerases 
[163, 164], and it has previously been shown that A3A/B can target DNA replication structures 
[31, 47, 165].  Taken together with our in vitro data, the possibility emerges that accumulation of 
base damage may act through several mechanisms to shift the endogenous patterns of deamination 
by AID/A3 enzymes. We suggest that this possibility merits further investigation.  
Since the AID/A3 enzymes may be active in DNA regions containing damaged DNA, it is 
also tempting to speculate that they may in this manner play a role in DNA repair, perhaps through 
instigating recruitment of mismatch repair or base excision pathways which are known to follow 
their deaminating activities[8, 167, 168]. As, previously mentioned, APOBEC3G (A3G) has been 
shown to increase efficiency of DSB repair in Lymphoma cells exposed to ionizing radiation 
[72,174]. A3G multimers were shown to associate with the ssDNA regions and end termini of 
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resected DSBs. In order for DSB repair rate to be maintained the ability to deaminate the DNA 
was required, and thus other members of the AID/APOBEC3 family may play similar roles. In a 
similar vein, A3A is directly involved in activating the DNA damage response in several cell types 
[175]. A3A was shown to be involved in phosphorylation of several DNA damage response 
signalling elements such as checkpoint kinase 2 and Replication Protein A (RPA), which are key 
checkpoint proteins in the cell cycle.  In addition, A3A targets the lagging strand of nuclear DNA 
undergoing replication and may lead to cell cycle arrest when upregulated. Taken together with 
our results that AID, A3A and A3B act efficiently on the most frequently found forms of base 














5. Future Directions 
 This project has laid the groundwork for many more projects in the future. The fact that 
these enzymes deaminate these bases in vitro does not prove that they do in vivo. The natural 
progression for this project would be to move to cellular assays. First, it would be useful to 
determine if these enzymes would still be active in cells containing high levels of oxidative or 
alkylative species. One could test this by incubating cells expressing AID, A3A or A3B with a 
weak oxidizing agent such as tert-butyl hydroxide, then purifying the enzymes to check and see if 
they are still active. Another interesting way to study AID/A3 activity in cell culture would be to 
measure induction of ƴ-H2AX foci in cells expressing these enzymes. ƴ-H2AX histones are 
indicative of DNA damage occurrence such as double-strand breaks. One can then use a 
fluorescent antibody to measure the amount of ƴ-H2AX in these cells compared to cells which are 
not expressing these enzymes. Perhaps the expression of these enzymes in cells cultured in the 
presence of a DNA oxidizing or alkylating agents would cause an exponential increase in ƴ-H2AX 
number. Conversely, if these enzymes recognize damaged DNA in order to  act as recruiting 
scaffolds for DNA repair proteins, one is expected to observe fewer ƴ-H2AX foci. This thesis has 
only scratched the surface of the interactions that may be occurring between AID/APOBEC3 and 
damaged DNA at a cellular level. As well as the experiments mentioned above, further 
investigation into the other members of the AID/APOBEC family with these assays may also lead 
to interesting results. As previously mentioned, the catalytic loop in this family of enzymes is 
highly conserved and thus it would be interesting to see if the pattern of activity I have discovered 
with this work holds true within other members of the family. There are many directions to take 
this project in the future. Hopefully, this project will serve as a basis for unraveling the mystery of 
how AID/A3 enzymes interact with damaged DNA in vivo. 
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6. Concluding Remarks 
Here we have shown that the cytidine deaminases AID, A3A and A3B can efficiently 
deaminate cytidines neighboring oxidized and alkylated DNA adducts. We have found, through 
structural modeling, that damaged and non-damaged bases rely on the substrate specificity loop(s) 
present on the surfaces of these enzymes to regulate access to the catalytic pocket. The alkylated 
and oxidized groups of the damaged DNA bases seem to show preference for specific regions 
within the loops compared to their non-damaged counterparts. We have also found that the purine 
bases in the -1 position tend to align with a second pocket close to the catalytic pocket. As of now, 
it is unclear what role these enzymes play within cells experiencing genome structural instability. 
However, it is clear that the relationship between AID/A3 enzymes and DNA damage is not as 
simple as previously speculated: not only do these enzymes cause DNA damage as previously 
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